ARTAN生物与Syenex VivoCell平台合作，实现下一代密码子抑制剂在衰老研究中的精准体内递送-动脉网

ARTAN Bio Partners with Syenex VivoCell Platform for Precision in vivo Delivery of Next-Generation Codon Suppressors for Aging

CISION 等信源发布 2025-06-30 19:45



可切换为仅中文







HOUSTON

休斯顿

and

和

CHICAGO

芝加哥

，

June 30, 2025

2025年6月30日

/PRNewswire/ --

ARTAN Bio

阿尔坦生物公司

, a community-backed biotechnology company developing therapeutics to reverse epigenetic changes associated with aging and age-related disease, and

，一家由社区支持的生物技术公司，致力于开发逆转与衰老和年龄相关疾病相关的表观遗传变化的治疗方法，以及

Syenex

西恩耐克斯

, an open-science genetic medicines platform company, today announced a strategic collaboration to access Syenex's precision

，一家开放科学的基因药物平台公司，今天宣布了一项战略合作，以获取Syenex的精准技术

in vivo

体内

delivery technologies, the VivoCell Platform, for ARTAN's lead drug, ARTAN-102.

递送技术，VivoCell平台，用于ARTAN的主导药物ARTAN-102。

继续阅读

Artan Bio and Syenex for precision in vivo delivery

Artan Bio 和 Syenex 用于精准的体内递送

Under the agreement, Syenex will provide ARTAN access to the

根据协议，Syenex 将为 ARTAN 提供访问权限

VivoCell

维沃赛尔

Platform

平台

and support the development of precision

并支持精准发展的推进

in vivo

体内

delivery vehicles tailored to ARTAN's codon suppressor platform, all under a non-exclusive program license option. The goal is to accelerate the timeline of ARTAN's program from in vitro proof-of-concept to IND-enabling studies while maintaining a maximally capital-efficient path for ARTAN.

为ARTAN的密码子抑制平台定制的递送载体，均在非独占项目许可选项下进行。目标是加速ARTAN项目从体外概念验证到支持IND的研究的时间线，同时保持对ARTAN来说最节省资本的路径。

Dr.

博士

Michael Torres

迈克尔·托雷斯

, Co-Founder & Chief Scientific Officer of ARTAN Bio

，ARTAN Bio联合创始人兼首席科学官

，

said, 'Precise, efficient delivery is critical to maximizing the potential of ARTAN-102. Syenex's track record in delivery vehicle innovation and manufacturing scale makes them a natural partner as we progress toward IND-enabling studies.'

说：“精确、高效的递送对于最大化ARTAN-102的潜力至关重要。Syenex在递送载体创新和制造规模方面的记录使他们成为我们迈向IND研究的天然合作伙伴。”

Jay Rosanelli

杰·罗萨内利

, Chief Executive Officer of Syenex

，Syenex首席执行官

, added, 'ARTAN Bio has generated strong preclinical data on the therapeutic potential of their lead drug candidate, ARTAN-102. By combining their codon suppressor platform with our VivoCell Platform, we aim to shorten development timelines and unlock treatment options for aging and age-related disease.'.

，补充道：“ARTAN Bio已经就其主要候选药物ARTAN-102的治疗潜力生成了强有力的临床前数据。通过将他们的密码子抑制平台与我们的VivoCell平台相结合，我们旨在缩短开发时间，并为衰老和与年龄相关的疾病解锁治疗选择。”

Collaboration scope

协作范围

Rapid Prototyping

快速原型制作

– Platform Access to the complete VivoCell Platform including libraries of precision delivery components supported by Syenex pre-clinical scale prototyping and production support.

– 平台访问完整的VivoCell平台，包括由Syenex支持的临床前规模原型设计和生产支持的精准递送组件库。

Manufacturing Scale-Up

制造规模扩大

– Prototypes to be transferred to Syenex CDMO partner for GMP scale-up.

– 原型将转移至Syenex CDMO合作伙伴，以进行GMP规模扩大。

Option Rights –

期权权利 –

Non-exclusive Program License option for the clinical delivery vehicle composition.

非独家程序许可选项，适用于临床交付载体组合。

Financial terms were not disclosed.

财务条款未披露。

About ARTAN Bio

关于ARTAN生物公司

ARTAN Bio is developing first-in-class therapeutics to restore full-length, functional proteins involved in aging and age-related disease. The Company's research is supported by a

ARTAN Bio公司正在开发首创的治疗药物，以恢复与衰老和年龄相关疾病有关的全长功能性蛋白质。该公司研究得到了支持。

decentralized

去中心化的

scientific community of stakeholders committed to accelerating cures for aging and rare genetic diseases. For more information, visit

致力于加速衰老和罕见遗传疾病治疗的科学界利益相关者社区。欲了解更多信息，请访问

www.artan.bio

and

和

vitarna.xyz

维塔纳.xyz

About Syenex

关于Syenex

Syenex is an open-science biotechnology platform company that enables developers to program cells with precision and scale. Leveraging synthetic biology and a global network of contract development and manufacturing organizations (CDMOs), Syenex provides plug-and-play delivery platforms—spanning discovery through GMP manufacturing—so genetic medicine developers can rapidly advance ideas to clinical impact.

Syenex是一家开放科学的生物技术平台公司，使开发者能够以精确和规模编程细胞。通过利用合成生物学和全球合同开发与制造组织（CDMO）网络，Syenex提供了即插即用的交付平台——涵盖从发现到GMP生产的全过程——从而使基因药物开发者能够快速将创意转化为临床影响。

Founded in 2022, Syenex has assembled a portfolio of cell-specific .

Syenex 成立于2022年，已经汇集了一系列特定细胞的组合。

ex vivo

离体

and

和

in vivo

体内

delivery platforms and over 50 partnerships with industry leaders across biopharma and academia. Learn more at

交付平台，并与生物制药和学术界的行业领导者建立了50多个合作伙伴关系。欲了解更多信息，请访问

www.syenex.com